ClinicalTrials.gg
CompletedNCT02156466Updated Jan 19, 2017Results posted

Multiple Ascending Dose Trial of MSB0010841 (Anti-IL17A/F Nanobody) in Psoriasis Subjects

A Phase 1 interventional study of MSB0010841 and MSB0010841 in Psoriasis, sponsored by Merck KGaA, Darmstadt, Germany. Completed at 1 site in Germany. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2017-01-19.

Sponsored by Merck KGaA, Darmstadt, Germany · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
41
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 299 studies in Psoriasis with a site in Germany — 13 open to participants now, 30 under way, 15 of them phase 3. Psoriasis · Germany.

Enrollment
207th of 260
41 · median 196
Started
2014
with 18 others
Phase 1
26 of 299
none open now
Registered
120th of 299
by date

Among the 299 studies in Psoriasis with a site in Germany, this one is the 207th largest by enrollment of the 260 interventional ones that give a count, is one of 19 that started in 2014, is one of 26 in phase 1, and was the 120th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

13 of the 299 studies in Psoriasis with a site in Germany are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 299 studies in Psoriasis with a site in Germany, or all of them as a file.
02

Study summary

This is a multicenter, Phase 1, randomized, double-blind, placebo-controlled trial in subjects with moderate to severe psoriasis to assess the safety, tolerability, immunogenicity, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of multiple subcutaneous ascending doses of MSB0010841 (Anti-interleukin-17A/F [Anti-IL-17A/F] Nanobody).

03

Conditions studied

  • Psoriasis

Browse trials for

Keywords

  • Psoriasis
  • MSB0010841
  • Anti-IL17A/F Nanobody
  • M1095
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Chronic plaque psoriasis for at least 6 months before screening
  • Greater than or equal to (>=) 10% of BSA with plaques
  • Psoriasis Area and Severity Index (PASI) >=12
  • Static Physician's Global Assessment (sPGA) >=3 (where scores range from 0 [clear of disease] to 5 [severe disease]) at the screening and baseline visits
  • Other protocol defined inclusion criteria could apply

Exclusion criteria

Exclusion Criteria:

  • Any condition, including protocol-specified laboratory findings and findings in the medical history or in the pre-trial assessments which in the Investigator's opinion constitutes a risk or a for the subject's participation in the trial or that could interfere with the trial objectives, conduct or evaluation
  • Currently having a form of non-plaque psoriasis as specified in the protocol
  • Drug induced psoriasis
  • Biological treatments as specified in the protocol, within 3 months prior to Day 1
  • Systemic or phototherapy as specified in the protocol, within 1 month prior to Day 1
  • Use of anti-coagulant medications and/or antiplatelet medications as defined in the protocol
  • Use of aspirin as defined in the protocol
  • Topical treatments other than low-strength or lower-mid strength corticosteroids on the face, scalp, axillae, and/or groin within 1 month prior to Day 1
  • Any previous treatment with an agent targeting interleukin (IL)-17, IL-12 and/or IL-23 as specified in the protocol
  • Other protocol defined exclusion criteria could apply
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    MSB0010841 30 mg

    Drug: MSB0010841

  • Experimental
    MSB0010841 60 mg

    Drug: MSB0010841

  • Experimental
    MSB0010841 120 mg

    Drug: MSB0010841

  • Experimental
    MSB0010841 240 mg

    Drug: MSB0010841

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • MSB0010841(Anti- IL-17A/F Nanobody) will be administered at a dose of 30 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.

    Also known as: Anti-IL-17A/F Nanobody, M1095

  • MSB0010841 will be administered at a dose of 60 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.

    Also known as: Anti-IL-17A/F Nanobody, M1095

  • MSB0010841 will be administered at a dose of 120 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.

    Also known as: Anti-IL-17A/F Nanobody, M1095

  • MSB0010841 will be administered at a dose of 240 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.

    Also known as: Anti-IL-17A/F Nanobody, M1095

  • DrugPlacebo

    Placebo matched to MSB0010841 will be administered as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.

06

What researchers measure

Primary outcomes

  1. Number of Subjects With Treatment Emergent Adverse Events (TEAEs)

    An adverse event (AE) was defined as any untoward medical occurrence which does not necessarily have a causal relationship with this the study drug. An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug or worsening of pre-existing medical condition, whether or not related to study drug. TEAEs were the AEs occurring or worsening after treatment administration.

    Time frame: Baseline up to Day 85

  2. Number of Subjects With Local Injection Site Reactions (ISRs)

    The injection site was assessed by the Principal Investigator (PI) or his/her designee for local reactions such as redness, swelling, indurations or bruising, and by the subject for itching. Redness and bruising were scaled as None (no visible redness or bruising present); Mild (less than or equal to \[\<=\] 2.0 centimeters \[cm\] redness or bruising area); Moderate (greater than \[\>\] 2 to \<=5.0 cm redness or bruising area); Severe (\>5.0 cm redness or bruising area). Swelling was scaled as None (no swelling detected); Mild (palpable 'firmness' only); Moderate (\<= 4 cm swelling); Severe (\>4 cm swelling). Induration was scaled as None (no induration); Mild (able to move skin parallel to plane (sliding) and perpendicular to skin (pinching up); Moderate (able to slide skin, unable to pinch skin); Severe (unable to slide or pinch skin). Itching was scaled as No itching; Mild itching; Moderate itching and Severe itching. Subjects who reported any of the local ISRs were reported.

    Time frame: Day 1, 2,8, 15, 16, 22, 29, 30, 36, 43

  3. Amount of Pain at Injection Site Assessed By Visual Analog Scale (VAS)

    Subjects were asked to assess their severity of injection site pain on a 100 millimeter (mm) VAS, where 0 = no pain and 100 = worst possible pain. Mean of amount of pain was calculated for the subjects having a value \> 0. Maximum values per subjects (over injection site areas) are used for counting the amount of pain at injection site. Maximum pain scores recorded among all participants analysed in each arm are reported for each time point.

    Time frame: Day 1, 2, 8, 15, 16, 22, 29, 30, 36, 43

  4. Percentage of Subjects With Anti-MSB0010841 Binding Antibodies (Anti-Drug Antibodies [ADA])

    Data were presented for MSB0010841 combined group and placebo.

    Time frame: Baseline up to Day 85

  5. Levels of Anti-MSB0010841 Antibody Titers

    Time frame: Day 8, 15 (pre-dose), 22, 29 (pre-dose), 36, 43, 63 and 85

  6. Levels of Pre-existing Anti-MSB0010841 Antibody Titers

    Time frame: Pre-dose on Day 1

  7. MSB0010841 Serum Concentration Over Time After First Dose

    Time frame: 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-first dose (Day 1)

  8. MSB0010841 Serum Concentration Over Time After Second Dose

    Time frame: 0 hours (pre-dose), 24, 72, 96, 168, 336 hours post-second dose (Day 15)

  9. MSB0010841 Serum Concentration Over Time After Third Dose

    Time frame: 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)

  10. Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) Post First Dose of MSB0010841

    Area under the serum concentration-time curve (AUC) from time zero to the last sampling time point at which the concentration is at or above lower limit of quantification (LLOQ).

    Time frame: 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-first dose (Day 1)

  11. Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) Post Third Dose of MSB0010841

    Area under the serum concentration-time curve (AUC) from time zero to the last sampling time point at which the concentration is at or above LLOQ.

    Time frame: 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)

  12. Area Under the Concentration-Time Curve From Time Zero up to Time Tau (AUCtau) Post First Dose of MSB0010841

    Area under the concentration-time curve from time zero up to time Tau, where Tau is the dosing interval (336 hours).

    Time frame: 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-first dose (Day 1)

  13. Area Under the Concentration-Time Curve From Time Zero up to Time Tau (AUCtau) Post Third Dose of MSB0010841

    Area under the concentration-time curve from time zero up to time Tau, where Tau is the dosing interval (336 hours).

    Time frame: 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-third dose (Day 29)

  14. Area Under the Concentration-time Curve From Time Zero to Infinity (AUC 0-inf) Post Third Dose of MSB0010841

    Area under the serum concentration-time curve from time zero to infinity (AUC0-inf). AUC0-infcalculated as AUC0-t + AUCextra. AUCextra represents the extrapolated part of AUC0-inf calculated by Clast calc/λz, where Clast calc is the calculated concentration at the last sampling time point at which the measured concentration is at or above LLOQ and λz is the terminal rate constant determined from the terminal slope of the log transformed concentration curve using linear regression on terminal data points of the curve.

    Time frame: 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)

  15. Observed Serum Concentration Immediately Before First Dose (Cpre) of MSB0010841

    The observed serum concentration immediately before the first dose.

    Time frame: Pre-dose (0 hours) on Day 1

  16. Observed Serum Concentration Immediately Before Third Dose (Cpre) of MSB0010841

    The observed serum concentration immediately before the third dose.

    Time frame: Pre-dose (0 hours) on Day 29

  17. Minimum Concentration Observed (Cmin) During First Dosing Interval of MSB0010841

    The observed minimum serum concentration determined directly from the serum concentration-time profile of each subject.

    Time frame: 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-first dose (Day 1)

  18. Minimum Concentration Observed (Cmin) During Third Dosing Interval of MSB0010841

    The observed minimum serum concentration determined directly from the serum concentration-time profile of each subject.

    Time frame: 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)

  19. Maximum Concentration Observed (Cmax) Post First Dose of MSB0010841

    Time frame: 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-first dose (Day 1)

  20. Maximum Concentration Observed (Cmax) Post Third Dose of MSB0010841

    Time frame: 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)

  21. Average Concentration (Cav) Post First Dose of MSB0010841

    Cav was calculated by AUCtau/tau. Where tau is the dosing interval (336 hours).

    Time frame: 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-first dose (Day 1)

  22. Average Concentration (Cav) Post Third Dose of MSB0010841

    Cav was calculated by AUCtau/tau. Where tau is the dosing interval (336 hours).

    Time frame: 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)

  23. Mean Residence Time (MRT0-t) Post First Dose of MSB0010841

    MRT is the average time at which the number of absorbed molecules reside in the body, after single-dose administration, and calculated as AUMC(0-t)/AUC(0-t) where AUMC(0-t) is area under the plasma concentration-time first moment curve from time zero to time t (336 hours) and AUC(0-t) is the area under the plasma concentration-time curve from time zero to tome t (336 hours).

    Time frame: 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-first dose (Day 1)

  24. Mean Residence Time (MRT0-t) Post Third Dose of MSB0010841

    MRT is the average time at which the number of absorbed molecules reside in the body, after single-dose administration, and calculated as AUMC(0-t)/AUC(0-t) where AUMC(0-t) is area under the plasma concentration-time first moment curve from time zero to time t (336 hours) and AUC(0-t) is the area under the plasma concentration-time curve from time zero to tome t (336 hours).

    Time frame: 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-third dose (Day 29)

  25. Mean Residence Time of Drug in the Body From Time Zero Extrapolated to Infinity (MRT(0-inf) Post Third Dose of MSB0010841

    Mean residence time of drug in the body from time zero extrapolated to infinity, based on the last predicted concentration at tlast.

    Time frame: 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)

  26. Time to Reach Maximum Observed Concentration (Tmax) Post First Dose of MSB0010841

    Time frame: 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-first dose (Day 1)

  27. Time to Maximum Observed Concentration (Tmax) Post Second Dose of MSB0010841

    Time frame: 0 hours (pre-dose), 24, 72, 96, 168, 336 hours post-second dose (Day 15)

  28. Time to Reach Maximum Observed Concentration (Tmax) Post Third Dose of MSB0010841

    Time frame: 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)

  29. Apparent Terminal Half-life (t1/2) Post Third Dose of MSB0010841

    Terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life is calculated by dividing the natural logarithm to the base e (Log e) multiplied by (\*) 2/ λz, where 'λz' is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.

    Time frame: 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)

  30. Terminal Rate Constant (λz) Post Third Dose of MSB0010841

    Terminal rate constant was determined from the terminal slope of the logtransformed concentration curve using linear regression on terminal data points of the curve

    Time frame: 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)

  31. Apparent Clearance (CL/f) Post Third Dose of MSB0010841

    Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent clearance after oral dose (CL/f) is influenced by the fraction absorbed.

    Time frame: 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)

  32. Apparent Volume of Distribution During Terminal Phase (Vz/f) Post Third Dose of MSB0010841

    Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Apparent volume of distribution during the terminal phase, calculated as Vz = Dose/AUC0-inf multiplied by elimination rate constant \[λz\]) following first dose and Dose/(AUCtau multiplied by λz) after third dose.

    Time frame: 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)

  33. Percentage Peak-Trough Fluctuation (PTF) Post First Dose of MSB0010841

    The peak trough fluctuation within one dosing interval, calculated as PTF (%) = (\[Cmax - Cmin\]/Cav ) multiplied by 100

    Time frame: 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-first dose (Day 1)

  34. Percentage Peak-Trough Fluctuation (PTF) Post Third Dose of MSB0010841

    The peak trough fluctuation within one dosing interval, calculated as PTF (%) = (\[Cmax - Cmin\]/Cav ) multiplied by 100

    Time frame: 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)

  35. Accumulation Ratio of Cmax (Racc (Cmax))

    Accumulation ratio for Cmax was calculated as Cmax, after third dose / Cmax, after first dose.

    Time frame: 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-first dose (Day 1) and 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)

  36. Accumulation Ratio of AUC (Racc(AUC))

    Accumulation ratio for AUC, calculated as area under the serum concentration-time curve within one complete dosing interval at third dose divided by area under the serum concentration-time curve within one complete dosing interval at first dose.

    Time frame: 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-first dose (Day 1) and 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)

  37. Maximum Observed Concentration (Cmax) Post Second Dose of MSB0010841

    Time frame: 0 hours (pre-dose), 24, 72, 96, 168, 336 hours post-second dose (Day 15)

  38. Observed Serum Concentration Immediately Before Second Dose (Cpre) of MSB0010841

    The observed serum concentration immediately before second dose.

    Time frame: Pre-dose (0 hours) on Day 15

Secondary outcomes

  1. Percentage of Subjects With 50% or 75% Improvement From Baseline in Psoriasis Area and Severity Index (PASI) Score

    PASI: a physician assessed index that measured psoriasis severity and evaluated erythema, infiltration, and desquamation (scaling) on different body areas including the head, upper extremities, the trunk, and lower extremities. T Erythema, infiltration, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) was multiplied by the degree of involvement for each anatomic region and then multiplied by a constant. These values for each anatomic region are summed to yield the PASI score. PASI score ranged from 0 to 72, with higher scores reflecting greater disease severity. PASI 50% or 75% was defined as the percentage of participants who achieved \>=50 or 75% improvement in PASI score from Baseline.

    Time frame: Baseline up to Day 85

  2. Mean Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Day 43

    PASI: a physician assessed index that measured psoriasis severity and evaluated erythema, infiltration, and desquamation (scaling) on different body areas including the head, upper extremities, the trunk, and lower extremities. T Erythema, infiltration, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) was multiplied by the degree of involvement for each anatomic region and then multiplied by a constant. These values for each anatomic region are summed to yield the PASI score. PASI score ranged from 0 to 72, with higher scores reflecting greater disease severity. PASI 50% or 75% was defined as the percentage of subjects who achieved \>=50 or 75% improvement in PASI score from Baseline.

    Time frame: Baseline, Day 43

  3. Percentage of Subjects With Static Physician's Global Assessment (sPGA) Score of Minimal or Clear and With at Least 2 Level Reduction From Baseline

    The static Physician's Global Assessment (sPGA) scale rated the investigator's overall clinical assessment of a subjects plaque thickness, erythema, and scaling on a 6-point scale ranging from 0 (clear, except for residual discoloration) to 5 (majority of plaques have severe thickness, erythema, and scale). To assign a sPGA score, the investigator examined all psoriatic lesions and assigned a severity score ranging from 0 to 5 for thickness, erythema, and scaling. Scores for thickness, erythema, and scaling are summed and the mean of these 3 scores equals the overall sPGA score. Overall sPGA score ranged from 0 to 5, where lower scores indicate clinical improvement. Percentage of subjects who achieved a sPGA rating of 0 (clear) or 1 (minimal) and had at Least 2 level reduction from Baseline score were reported.

    Time frame: Day 8, 15, 22, 29, 36, 43, 50, 85

  4. Mean Percent Change From Baseline in the Body Surface Area (BSA) Affected by Psoriasis at Day 8, 15, 22, 29, 36, 43, 50 and 85

    The BSA is the physician's evaluation for the extent of disease. The entire body area is divided into 4 districts: head, upper limbs, trunk and lower limbs to which corresponds the 10%, 20%, 30% and 40% of the entire body surface respectively. The investigator assesses the percentage of the subjects' body surface area affected by psoriasis in each district. The final affected BSA value is the sum of the percentage of each district.

    Time frame: Baseline, Day 8, 15, 22, 29, 36, 43, 50 and 85

  5. Percentage of Subjects With Exacerbation of Psoriasis

    Psoriasis exacerbation was defined as either a worsening of 25% over the baseline value of the PASI score (PASI score at any visit \>=125% of baseline PASI).

    Time frame: Baseline up to Day 85

07

Results

Posted Jan 19, 2017
Limitations and caveats
As AUCextra was more than 20% of AUC0-inf after first dose, AUCextra and all values derived from λz were regarded as implausible and "AUC0-inf", "MRT0-inf", "t1/2", "λz", "CL/f", and "Vz/f" were not calculated after first dose.

Participant flow

Participant flow — Overall Study
MilestoneMSB0010841 30 mgMSB0010841 60 mgMSB0010841 120 mgMSB0010841 240 mgPlacebo
Started88898
Completed88778
Not completed00120
Withdrew: Adverse event00110
Withdrew: Quantiferon positivity00010

Outcome measures

PrimaryNumber of Subjects With Treatment Emergent Adverse Events (TEAEs)

An adverse event (AE) was defined as any untoward medical occurrence which does not necessarily have a causal relationship with this the study drug. An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug or worsening of pre-existing medical condition, whether or not related to study drug. TEAEs were the AEs occurring or worsening after treatment administration.

Time frame:
Baseline up to Day 85
Reported as:
Number · subjects
Number of Subjects With Treatment Emergent Adverse Events (TEAEs)
subjectsMSB0010841 30 mgMSB0010841 60 mgMSB0010841 120 mgMSB0010841 240 mgPlacebo
Number of Subjects With Treatment Emergent Adverse Events (TEAEs)65566
PrimaryNumber of Subjects With Local Injection Site Reactions (ISRs)

The injection site was assessed by the Principal Investigator (PI) or his/her designee for local reactions such as redness, swelling, indurations or bruising, and by the subject for itching. Redness and bruising were scaled as None (no visible redness or bruising present); Mild (less than or equal to \[\<=\] 2.0 centimeters \[cm\] redness or bruising area); Moderate (greater than \[\>\] 2 to \<=5.0 cm redness or bruising area); Severe (\>5.0 cm redness or bruising area). Swelling was scaled as None (no swelling detected); Mild (palpable 'firmness' only); Moderate (\<= 4 cm swelling); Severe (\>4 cm swelling). Induration was scaled as None (no induration); Mild (able to move skin parallel to plane (sliding) and perpendicular to skin (pinching up); Moderate (able to slide skin, unable to pinch skin); Severe (unable to slide or pinch skin). Itching was scaled as No itching; Mild itching; Moderate itching and Severe itching. Subjects who reported any of the local ISRs were reported.

Time frame:
Day 1, 2,8, 15, 16, 22, 29, 30, 36, 43
Reported as:
Number · subjects
Number of Subjects With Local Injection Site Reactions (ISRs)
subjectsMSB0010841 30 mgMSB0010841 60 mgMSB0010841 120 mgMSB0010841 240 mgPlacebo
Day 1 Bruising: none (n=8,8,8,9,8)88898
Day 1 Indurations: none (n=8,8,8,9,8)88798
Day 1 Indurations: mild (n=8,8,8,9,8)00100
Day 1 Itching: none (n=8,8,8,9,8)88889
Day 1 Itching: mild (n=8,8,8,9,8)00010
Day 1 Redness: none (n=8,8,8,9,8)87886
Day 1 Redness: mild (n=8,8,8,9,8)01012
Day 1 Swelling: none (n=8,8,8,9,8)87898
Day 1 Swelling: mild (n=8,8,8,9,8)01000
Day 2 Bruising: none (n=8,8,8,9,8)58898
Day 2 Bruising: mild (n=8,8,8,9,8)30000
Day 2 Indurations: none (n=8,8,8,9,8)88898
Day 2 Itching: none (n=8,8,8,9,8)88898
Day 2 Redness: none (n=8,8,8,9,8)88898
Day 2 Swelling: none (n=8,8,8,9,8)88898
Day 8 Bruising: none (n=8,8,8,8,8)88888
Day 8 Indurations: none (n=8,8,8,8,8)88888
Day 8 Itching: none (n=8,8,8,8,8)88888
Day 8 Redness: none (n=8,8,8,8,8)78888
Day 8 Redness: mild (n=8,8,8,8,8)10000
Day 8 Swelling: none (n=8,8,8,8,8)88888
Day 15 Bruising: none (n=8,8,8,8,8)88888
Day 15 Indurations: none (n=8,8,8,8,8)88888
Day 15 Itching: none (n=8,8,8,8,8)88888
Day 15 Redness: none (n=8,8,8,8,8)87788
Day 15 Redness: mild (n=8,8,8,8,8)01000
Day 15 Redness: moderate (n=8,8,8,8,8)00100
Day 15 Swelling: none (n=8,8,8,8,8)88888
Day 16 Bruising: none (n=8,8,8,8,8)87878
Day 16 Bruising: mild (n=8,8,8,8,8)01010
Day 16 Indurations: none (n=8,8,8,8,8)88888
Day 16 Itching: none (n=8,8,8,8,8)88888
Day 16 Redness: none (n=8,8,8,8,8)78888
Day 16 Redness: mild (n=8,8,8,8,8)10000
Day 16 Swelling: none (n=8,8,8,8,8)88788
Day 16 Swelling: mild (n=8,8,8,8,8)00100
Day 22 Bruising: none (n=8,8,8,8,8)88878
Day 22 Bruising: mild (n=8,8,8,8,8)00010
Day 22 Indurations: none (n=8,8,8,8,8)88788
Day 22 Indurations: severe (n=8,8,8,8,8)00100
Day 22 Itching: none (n=8,8,8,8,8)78888
Day 22 Itching: mild (n=8,8,8,8,8)10000
Day 22 Redness: none (n=8,8,8,8,8)88788
Day 22 Redness: severe (n=8,8,8,8,8)00100
Day 22 Swelling: none (n=8,8,8,8,8)88788
Day 22 Swelling: severe (n=8,8,8,8,8)00100
Day 29 Bruising: none (n=8,8,8,7,8)88878
Day 29 Indurations: none (n=8,8,7,7,8)88778
Day 29 Itching: none (n=8,8,8,7,8)88878
Day 29 Redness: none (n=8,8,8,8,8)88658
Day 29 Redness: mild (n=8,8,8,8,8)00220
Day 29 Redness: moderate (n=8,8,8,8,8)00010
Day 29 Swelling: none (n=8,8,8,7,8)88778
Day 29 Swelling: mild (n=8,8,8,7,8)00100
Day 30 Bruising: none (n=8,8,8,7,8)88768
Day 30 Bruising: mild (n=8,8,8,7,8)00110
Day 30 Indurations: none (n=8,8,7,7,8)88778
Day 30 Itching: none (n=8,8,7,7,8)88008
Day 30 Redness: none (n==8,8,7,7,8)88768
Day 30 Redness: moderate (n=8,8,7,7,8)00010
Day 30 Swelling: none (n=8,8,7,7,8)88778
Day 36 Bruising: none (n=7,8,7,7,8)78768
Day 36 Bruising: mild (n=7,8,7,7,8)00010
Day 36 Indurations: none (n=8,8,7,7,7)88777
Day 36 Itching: none (n=7,8,7,6,8)78768
Day 43 Bruising: none (n=8,8,8,8,8)88888
Day 43 Indurations: none (n=8,8,8,8,8)88888
Day 43 Itching: none (8,8,8,8,8)88888
Day 43 Redness: none (n=8,8,8,8,8)88788
Day 43 Redness: moderate (n=8,8,8,8,8)00100
Day 43 Swelling: none (n=8,8,8,8,8)88888
PrimaryAmount of Pain at Injection Site Assessed By Visual Analog Scale (VAS)

Subjects were asked to assess their severity of injection site pain on a 100 millimeter (mm) VAS, where 0 = no pain and 100 = worst possible pain. Mean of amount of pain was calculated for the subjects having a value \> 0. Maximum values per subjects (over injection site areas) are used for counting the amount of pain at injection site. Maximum pain scores recorded among all participants analysed in each arm are reported for each time point.

Time frame:
Day 1, 2, 8, 15, 16, 22, 29, 30, 36, 43
Reported as:
Number · mm
Amount of Pain at Injection Site Assessed By Visual Analog Scale (VAS)
mmMSB0010841 30 mgMSB0010841 60 mgMSB0010841 120 mgMSB0010841 240 mgPlacebo
Day 1 (n=3,2,3,2,0)7474NA
Day 2 (n=1,1,1,1,0)1111NA
Day 8 (n=1,1,0,0,0)11NANANA
Day 15 (n=2,1,3,0,0)537NANA
Day 16 (n=0,0,0,0,2)NANANANA2
Day 22 (1,0,1,0,0)11NA1NANA
Day 29 (n=1,1,1,0,0)322NANA
Day 30 (1,0,1,1,0)2NA11NA
Day 36 (n=0,0,0,0,0)NANANANANA
Day 43 (n=0,0,0,0,0)NANANANANA
PrimaryPercentage of Subjects With Anti-MSB0010841 Binding Antibodies (Anti-Drug Antibodies [ADA])

Data were presented for MSB0010841 combined group and placebo.

Time frame:
Baseline up to Day 85
Reported as:
Number · percentage of subjects
Percentage of Subjects With Anti-MSB0010841 Binding Antibodies (Anti-Drug Antibodies [ADA])
percentage of subjectsMSB0010841 CombinedPlacebo
Percentage of Subjects With Anti-MSB0010841 Binding Antibodies (Anti-Drug Antibodies [ADA])30.337.5
PrimaryLevels of Anti-MSB0010841 Antibody Titers
Time frame:
Day 8, 15 (pre-dose), 22, 29 (pre-dose), 36, 43, 63 and 85
Reported as:
Number · log10titer
Levels of Anti-MSB0010841 Antibody Titers
log10titerADA Positive Subjects
Day 8 Subject 1: Placebo3.68
Day 8 Subject 2: Placebo3.68
Day 8 Subject 3: Placebo3.68
Day 8 Subject 4: MSB0010841 30 mg3.68
Day 8 Subject 5: MSB0010841 30 mg0
Day 8 Subject 6: MSB0010841 30 mg2.28
Day 8 Subject 7: MSB0010841 60 mg0
Day 8 Subject 8: MSB0010841 120 mg3.68
Day 8 Subject 9: MSB0010841 120 mg4.38
Day 8 Subject 10: MSB0010841 120 mg3.68
Day 8 Subject 11: MSB0010841 120 mg4.38
Day 8 Subject 12: MSB0010841 120 mg2.98
Day 8 Subject 13: MSB0010841 240 mg2.98
Day 15 (pre-dose) Subject 1: Placebo3.68
Day 15 (pre-dose) Subject 2: Placebo3.68
Day 15 (pre-dose) Subject 3: Placebo3.68
Day 15 (pre-dose) Subject 4: MSB0010841 30 mg3.68
Day 15 (pre-dose) Subject 5: MSB0010841 30 mg0
Day 15 (pre-dose) Subject 6: MSB0010841 30 mg2.28
Day 15 (pre-dose) Subject 7: MSB0010841 60 mg2.98
Day 15 (pre-dose) Subject 8: MSB0010841 120 mg5.78
Day 15 (pre-dose) Subject 9: MSB0010841 120 mg4.38
Day 15 (pre-dose) Subject 10: MSB0010841 120 mg3.68
Day 15 (pre-dose) Subject 11: MSB0010841 120 mg4.38
Day 15 (pre-dose) Subject 12: MSB0010841 120 mg2.98
Day 15 (pre-dose) Subject 13: MSB0010841 240 mg2.98
Day 22 Subject 1: Placebo3.68
Day 22 Subject 2: Placebo3.68
Day 22 Subject 3: Placebo3.68
Day 22 Subject 4: MSB0010841 30 mg3.68
Day 22 Subject 5: MSB0010841 30 mg2.98
Day 22 Subject 6: MSB0010841 30 mg2.98
Day 22 Subject 7: MSB0010841 60 mg2.28
Day 22 Subject 8: MSB0010841 120 mg2.98
Day 22 Subject 9: MSB0010841 120 mg4.38
Day 22 Subject 10: MSB0010841 120 mg3.68
Day 22 Subject 11: MSB0010841 120 mg4.38
Day 22 Subject 12: MSB0010841 120 mg2.98
Day 22 Subject 13: MSB0010841 240 mg2.98
Day 29 (pre-dose) Subject 1: Placebo3.68
Day 29 (pre-dose) Subject 2: Placebo3.68
Day 29 (pre-dose) Subject 3: Placebo3.68
Day 29 (pre-dose) Subject 4: MSB0010841 30 mg2.98
Day 29 (pre-dose) Subject 5: MSB0010841 30 mg0
Day 29 (pre-dose) Subject 6: MSB0010841 30 mg2.98
Day 29 (pre-dose) Subject 7: MSB0010841 60 mg2.28
Day 29 (pre-dose) Subject 8: MSB0010841 120 mg3.68
Day 29 (pre-dose) Subject 9: MSB0010841 120 mg3.68
Day 29 (pre-dose) Subject 10: MSB0010841 120 mg3.68
Day 29 (pre-dose) Subject 11: MSB0010841 120 mg4.38
Day 29 (pre-dose) Subject 12: MSB0010841 120 mg2.98
Day 29 (pre-dose) Subject 13: MSB0010841 240 mg2.98
Day 36 Subject 1: PlaceboNA
Day 36 Subject 2: Placebo3.68
Day 36 Subject 3: Placebo3.68
Day 36 Subject 4: MSB0010841 30 mg2.98
Day 36 Subject 5: MSB0010841 30 mg0
Day 36 Subject 6: MSB0010841 30 mg2.98
Day 36 Subject 7: MSB0010841 60 mg2.98
Day 36 Subject 8: MSB0010841 120 mgNA
Day 36 Subject 9: MSB0010841 120 mg3.68
Day 36 Subject 10: MSB0010841 120 mg4.38
Day 36 Subject 11: MSB0010841 120 mg4.38
Day 36 Subject 12: MSB0010841 120 mg3.68
Day 36 Subject 13: MSB0010841 240 mg2.98
Day 43 Subject 1: Placebo2.98
Day 43 Subject 2: Placebo3.68
Day 43 Subject 3: Placebo3.68
Day 43 Subject 4: MSB0010841 30 mg2.98
Day 43 Subject 5: MSB0010841 30 mg0
Day 43 Subject 6: MSB0010841 30 mg2.98
Day 43 Subject 7: MSB0010841 60 mg2.28
Day 43 Subject 8: MSB0010841 120 mg4.38
Day 43 Subject 9: MSB0010841 120 mg3.68
Day 43 Subject 10: MSB0010841 120 mg4.38
Day 43 Subject 11: MSB0010841 120 mg3.68
Day 43 Subject 12: MSB0010841 120 mg2.98
Day 43 Subject 13: MSB0010841 240 mg2.98
Day 63 Subject 1: Placebo3.68
Day 63 Subject 2: Placebo3.68
Day 63 Subject 3: Placebo3.68
Day 63 Subject 4: MSB0010841 30 mg4.38
Day 63 Subject 5: MSB0010841 30 mg0
Day 63 Subject 6: MSB0010841 30 mg2.98
Day 63 Subject 7: MSB0010841 60 mg2.28
Day 63 Subject 8: MSB0010841 120 mg2.98
Day 63 Subject 9: MSB0010841 120 mg3.68
Day 63 Subject 10: MSB0010841 120 mg3.68
Day 63 Subject 11: MSB0010841 120 mg3.68
Day 63 Subject 12: MSB0010841 120 mg3.68
Day 63 Subject 13: MSB0010841 240 mg2.98
Day 85 Subject 1: Placebo3.68
Day 85 Subject 2: Placebo3.68
Day 85 Subject 3: Placebo3.68
Day 85 Subject 4: MSB0010841 30 mg3.68
Day 85 Subject 5: MSB0010841 30 mg0
Day 85 Subject 6: MSB0010841 30 mg2.28
Day 85 Subject 7: MSB0010841 60 mg2.28
Day 85 Subject 8: MSB0010841 120 mg2.98
Day 85 Subject 9: MSB0010841 120 mg3.68
Day 85 Subject 10: MSB0010841 120 mg3.68
Day 85 Subject 11: MSB0010841 120 mg2.98
Day 85 Subject 12: MSB0010841 120 mg3.68
Day 85 Subject 13: MSB0010841 240 mg2.98
PrimaryLevels of Pre-existing Anti-MSB0010841 Antibody Titers
Time frame:
Pre-dose on Day 1
Reported as:
Number · log10titer
Levels of Pre-existing Anti-MSB0010841 Antibody Titers
log10titerADA Positive Subjects
Subject 1: Placebo2.98
Subject 2: Placebo3.68
Subject 3: Placebo3.68
Subject 4: MSB0010841 30 mg2.98
Subject 5: MSB0010841 30 mg0
Subject 6: MSB0010841 30 mg0
Subject 7: MSB0010841 60 mg0
Subject 8: MSB0010841 120 mg2.98
Subject 9: MSB0010841 120 mg5.08
Subject 10: MSB0010841 120 mg3.68
Subject 11: MSB0010841 120 mg3.68
Subject 12: MSB0010841 120 mg2.98
Subject 13: MSB0010841 240 mg0
PrimaryMSB0010841 Serum Concentration Over Time After First Dose
Time frame:
0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-first dose (Day 1)
Reported as:
Mean · nanogram/milliliter (ng/mL)
MSB0010841 Serum Concentration Over Time After First Dose
nanogram/milliliter (ng/mL)MSB0010841 30 mgMSB0010841 60 mgMSB0010841 120 mgMSB0010841 240 mg
0 hour (n=8,8,8,9)12.6 ± 35.710.0 ± 0.000.0 ± 0.000.0 ± 0.00
6 hour (n=8,8,8,9)907.5 ± 523.162097.1 ± 1391.432315.5 ± 787.024858.8 ± 2326.35
12 hour (n=8,8,8,9)1793.3 ± 761.233339.6 ± 1671.294983.1 ± 1501.419780.3 ± 4698.97
24 hour (n=8,8,8,9)2788.4 ± 895.895047.8 ± 1600.259131.3 ± 2838.0215357.6 ± 5295.18
32 hour (n=8,8,8,9)3037.3 ± 820.766028.1 ± 2269.6611372.4 ± 3499.3717135.2 ± 6032.66
72 hour (n=8,8,7,8)3190.4 ± 810.186492.9 ± 1472.2911284.1 ± 2562.8420536.6 ± 6716.38
96 hour (n=8,8,8,8)3155.8 ± 879.566423.8 ± 1824.4611790.0 ± 3319.3618732.9 ± 4670.66
168 hour (n=8,8,8,8)2665.5 ± 605.895179.5 ± 1126.7410318.6 ± 2837.8117761.9 ± 3072.48
336 hour (n=8,8,8,8)1704.3 ± 429.783951.0 ± 1353.926768.4 ± 2846.2411605.8 ± 2065.58
PrimaryMSB0010841 Serum Concentration Over Time After Second Dose
Time frame:
0 hours (pre-dose), 24, 72, 96, 168, 336 hours post-second dose (Day 15)
Reported as:
Mean · ng/mL
MSB0010841 Serum Concentration Over Time After Second Dose
ng/mLMSB0010841 30 mgMSB0010841 60 mgMSB0010841 120 mgMSB0010841 240 mg
0 hour1704.3 ± 429.783951.0 ± 1353.926768.4 ± 2846.2411605.8 ± 2065.58
24 hour3808.0 ± 980.687268.9 ± 3771.9815120.6 ± 3393.8427664.8 ± 9231.41
72 hour4309.0 ± 1265.459095.5 ± 2115.1617454.4 ± 4152.3229902.4 ± 7523.13
96 hour4020.5 ± 923.658514.4 ± 1849.4417081.4 ± 5056.1729223.5 ± 8336.26
168 hour3517.8 ± 877.967180.4 ± 1705.2414806.6 ± 5632.9922972.5 ± 11219.87
336 hour2306.5 ± 588.504492.9 ± 1398.6310468.9 ± 4376.7516454.5 ± 4548.85
PrimaryMSB0010841 Serum Concentration Over Time After Third Dose
Time frame:
0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)
Reported as:
Mean · ng/mL
MSB0010841 Serum Concentration Over Time After Third Dose
ng/mLMSB0010841 30 mgMSB0010841 60 mgMSB0010841 120 mgMSB0010841 240 mg
0 hour2306.5 ± 588.504492.9 ± 1398.6310417.7 ± 4724.8416173.6 ± 4837.78
6 hour3483.9 ± 1566.886200.1 ± 1391.3812725.0 ± 5573.1120452.3 ± 6683.19
12 hour3557.9 ± 1004.438615.5 ± 3093.4613361.0 ± 5959.2626051.4 ± 8770.65
24 hour4533.3 ± 1178.149969.9 ± 2494.6017523.1 ± 6140.3133651.7 ± 11590.56
32 hour4934.5 ± 1256.4710762.5 ± 2377.8818634.9 ± 5713.1438278.4 ± 13391.40
72 hour4936.0 ± 1387.5010345.6 ± 4586.2419813.1 ± 6381.2737166.4 ± 10103.58
96 hour4994.9 ± 1448.539047.6 ± 2760.2518260.1 ± 6602.9033909.3 ± 10219.54
168 hour4368.1 ± 1201.567715.4 ± 3019.9315585.3 ± 5625.6531375.9 ± 6826.50
336 hour2680.5 ± 859.355602.1 ± 3057.3412257.6 ± 7468.8520011.9 ± 6248.98
504 hour1802.0 ± 505.423109.1 ± 1519.668610.6 ± 5991.6812472.4 ± 4176.00
816 hour933.1 ± 376.761378.1 ± 834.664309.3 ± 4044.885064.6 ± 2070.93
1056 hour464.5 ± 257.13658.5 ± 391.392599.7 ± 2937.082475.9 ± 1391.08
1344 hour244.8 ± 162.24326.3 ± 230.871611.3 ± 2199.921345.7 ± 879.15
PrimaryArea Under the Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) Post First Dose of MSB0010841

Area under the serum concentration-time curve (AUC) from time zero to the last sampling time point at which the concentration is at or above lower limit of quantification (LLOQ).

Time frame:
0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-first dose (Day 1)
Reported as:
Geometric mean · day*microgram per milliliter (day*mcg/mL
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) Post First Dose of MSB0010841
day*microgram per milliliter (day*mcg/mLMSB0010841 30 mgMSB0010841 60 mgMSB0010841 120 mgMSB0010841 240 mg
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) Post First Dose of MSB001084133.6 ± 28.069.3 ± 18.9126.3 ± 28.5216.5 ± 23.4
PrimaryArea Under the Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) Post Third Dose of MSB0010841

Area under the serum concentration-time curve (AUC) from time zero to the last sampling time point at which the concentration is at or above LLOQ.

Time frame:
0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)
Reported as:
Geometric mean · day*mcg/mL
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) Post Third Dose of MSB0010841
day*mcg/mLMSB0010841 30 mgMSB0010841 60 mgMSB0010841 120 mgMSB0010841 240 mg
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) Post Third Dose of MSB001084193.7 ± 41.4170.3 ± 39.5371.7 ± 62.0663.4 ± 31.1
PrimaryArea Under the Concentration-Time Curve From Time Zero up to Time Tau (AUCtau) Post First Dose of MSB0010841

Area under the concentration-time curve from time zero up to time Tau, where Tau is the dosing interval (336 hours).

Time frame:
0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-first dose (Day 1)
Reported as:
Geometric mean · day*mcg/mL
Area Under the Concentration-Time Curve From Time Zero up to Time Tau (AUCtau) Post First Dose of MSB0010841
day*mcg/mLMSB0010841 30 mgMSB0010841 60 mgMSB0010841 120 mgMSB0010841 240 mg
Area Under the Concentration-Time Curve From Time Zero up to Time Tau (AUCtau) Post First Dose of MSB001084132.4 ± 31.268.3 ± 16.4114.6 ± 24.2222.2 ± 19.6
PrimaryArea Under the Concentration-Time Curve From Time Zero up to Time Tau (AUCtau) Post Third Dose of MSB0010841

Area under the concentration-time curve from time zero up to time Tau, where Tau is the dosing interval (336 hours).

Time frame:
0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-third dose (Day 29)
Reported as:
Geometric mean · day*mcg/mL
Area Under the Concentration-Time Curve From Time Zero up to Time Tau (AUCtau) Post Third Dose of MSB0010841
day*mcg/mLMSB0010841 30 mgMSB0010841 60 mgMSB0010841 120 mgMSB0010841 240 mg
Area Under the Concentration-Time Curve From Time Zero up to Time Tau (AUCtau) Post Third Dose of MSB001084154.2 ± 36.3104.1 ± 33.9203.2 ± 43.6397.6 ± 27.1
PrimaryArea Under the Concentration-time Curve From Time Zero to Infinity (AUC 0-inf) Post Third Dose of MSB0010841

Area under the serum concentration-time curve from time zero to infinity (AUC0-inf). AUC0-infcalculated as AUC0-t + AUCextra. AUCextra represents the extrapolated part of AUC0-inf calculated by Clast calc/λz, where Clast calc is the calculated concentration at the last sampling time point at which the measured concentration is at or above LLOQ and λz is the terminal rate constant determined from the terminal slope of the log transformed concentration curve using linear regression on terminal data points of the curve.

Time frame:
0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)
Reported as:
Geometric mean · day*ug/mL
Area Under the Concentration-time Curve From Time Zero to Infinity (AUC 0-inf) Post Third Dose of MSB0010841
day*ug/mLMSB0010841 30 mgMSB0010841 60 mgMSB0010841 120 mgMSB0010841 240 mg
Area Under the Concentration-time Curve From Time Zero to Infinity (AUC 0-inf) Post Third Dose of MSB001084197.6 ± 42.2174.9 ± 39.9392.6 ± 68.8680.9 ± 32.2
PrimaryObserved Serum Concentration Immediately Before First Dose (Cpre) of MSB0010841

The observed serum concentration immediately before the first dose.

Time frame:
Pre-dose (0 hours) on Day 1
Reported as:
Mean · mcg/mL
Observed Serum Concentration Immediately Before First Dose (Cpre) of MSB0010841
mcg/mLMSB0010841 30 mgMSB0010841 60 mgMSB0010841 120 mgMSB0010841 240 mg
Observed Serum Concentration Immediately Before First Dose (Cpre) of MSB00108410.01 ± 0.0360.00 ± 0.0000.00 ± 0.0000.00 ± 0.000
PrimaryObserved Serum Concentration Immediately Before Third Dose (Cpre) of MSB0010841

The observed serum concentration immediately before the third dose.

Time frame:
Pre-dose (0 hours) on Day 29
Reported as:
Mean · mcg/mL
Observed Serum Concentration Immediately Before Third Dose (Cpre) of MSB0010841
mcg/mLMSB0010841 30 mgMSB0010841 60 mgMSB0010841 120 mgMSB0010841 240 mg
Observed Serum Concentration Immediately Before Third Dose (Cpre) of MSB00108412.31 ± 0.594.49 ± 1.4010.42 ± 4.7216.17 ± 4.84
PrimaryMinimum Concentration Observed (Cmin) During First Dosing Interval of MSB0010841

The observed minimum serum concentration determined directly from the serum concentration-time profile of each subject.

Time frame:
0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-first dose (Day 1)
Reported as:
Mean · mcg/mL
Minimum Concentration Observed (Cmin) During First Dosing Interval of MSB0010841
mcg/mLMSB0010841 30 mgMSB0010841 60 mgMSB0010841 120 mgMSB0010841 240 mg
Minimum Concentration Observed (Cmin) During First Dosing Interval of MSB00108410.01 ± 0.0360.00 ± 0.0000.00 ± 0.0000.00 ± 0.000
PrimaryMinimum Concentration Observed (Cmin) During Third Dosing Interval of MSB0010841

The observed minimum serum concentration determined directly from the serum concentration-time profile of each subject.

Time frame:
0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)
Reported as:
Mean · mcg/mL
Minimum Concentration Observed (Cmin) During Third Dosing Interval of MSB0010841
mcg/mLMSB0010841 30 mgMSB0010841 60 mgMSB0010841 120 mgMSB0010841 240 mg
Minimum Concentration Observed (Cmin) During Third Dosing Interval of MSB00108412.30 ± 0.604.34 ± 1.4010.03 ± 4.9516.17 ± 4.84
PrimaryMaximum Concentration Observed (Cmax) Post First Dose of MSB0010841
Time frame:
0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-first dose (Day 1)
Reported as:
Geometric mean · mcg/mL
Maximum Concentration Observed (Cmax) Post First Dose of MSB0010841
mcg/mLMSB0010841 30 mgMSB0010841 60 mgMSB0010841 120 mgMSB0010841 240 mg
Maximum Concentration Observed (Cmax) Post First Dose of MSB00108413.3 ± 28.47.4 ± 22.912.5 ± 25.620.8 ± 30.3
PrimaryMaximum Concentration Observed (Cmax) Post Third Dose of MSB0010841
Time frame:
0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)
Reported as:
Geometric mean · mcg/mL
Maximum Concentration Observed (Cmax) Post Third Dose of MSB0010841
mcg/mLMSB0010841 30 mgMSB0010841 60 mgMSB0010841 120 mgMSB0010841 240 mg
Maximum Concentration Observed (Cmax) Post Third Dose of MSB00108415.14 ± 34.511.32 ± 29.719.74 ± 31.337.93 ± 32.2
PrimaryAverage Concentration (Cav) Post First Dose of MSB0010841

Cav was calculated by AUCtau/tau. Where tau is the dosing interval (336 hours).

Time frame:
0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-first dose (Day 1)
Reported as:
Geometric mean · mcg/mL
Average Concentration (Cav) Post First Dose of MSB0010841
mcg/mLMSB0010841 30 mgMSB0010841 60 mgMSB0010841 120 mgMSB0010841 240 mg
Average Concentration (Cav) Post First Dose of MSB00108412.315 ± 31.24.881 ± 16.48.187 ± 24.215.868 ± 19.6
PrimaryAverage Concentration (Cav) Post Third Dose of MSB0010841

Cav was calculated by AUCtau/tau. Where tau is the dosing interval (336 hours).

Time frame:
0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)
Reported as:
Geometric mean · mcg/mL
Average Concentration (Cav) Post Third Dose of MSB0010841
mcg/mLMSB0010841 30 mgMSB0010841 60 mgMSB0010841 120 mgMSB0010841 240 mg
Average Concentration (Cav) Post Third Dose of MSB00108413.87 ± 36.37.44 ± 33.914.51 ± 43.628.40 ± 27.1
PrimaryMean Residence Time (MRT0-t) Post First Dose of MSB0010841

MRT is the average time at which the number of absorbed molecules reside in the body, after single-dose administration, and calculated as AUMC(0-t)/AUC(0-t) where AUMC(0-t) is area under the plasma concentration-time first moment curve from time zero to time t (336 hours) and AUC(0-t) is the area under the plasma concentration-time curve from time zero to tome t (336 hours).

Time frame:
0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-first dose (Day 1)
Reported as:
Geometric mean · day
Mean Residence Time (MRT0-t) Post First Dose of MSB0010841
dayMSB0010841 30 mgMSB0010841 60 mgMSB0010841 120 mgMSB0010841 240 mg
Mean Residence Time (MRT0-t) Post First Dose of MSB00108416.528 ± 3.66.691 ± 8.16.638 ± 5.76.771 ± 5.3
PrimaryMean Residence Time (MRT0-t) Post Third Dose of MSB0010841

MRT is the average time at which the number of absorbed molecules reside in the body, after single-dose administration, and calculated as AUMC(0-t)/AUC(0-t) where AUMC(0-t) is area under the plasma concentration-time first moment curve from time zero to time t (336 hours) and AUC(0-t) is the area under the plasma concentration-time curve from time zero to tome t (336 hours).

Time frame:
0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-third dose (Day 29)
Reported as:
Geometric mean · day
Mean Residence Time (MRT0-t) Post Third Dose of MSB0010841
dayMSB0010841 30 mgMSB0010841 60 mgMSB0010841 120 mgMSB0010841 240 mg
Mean Residence Time (MRT0-t) Post Third Dose of MSB001084117.57 ± 11.215.68 ± 16.319.26 ± 32.016.38 ± 11.3
PrimaryMean Residence Time of Drug in the Body From Time Zero Extrapolated to Infinity (MRT(0-inf) Post Third Dose of MSB0010841

Mean residence time of drug in the body from time zero extrapolated to infinity, based on the last predicted concentration at tlast.

Time frame:
0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)
Reported as:
Geometric mean · day
Mean Residence Time of Drug in the Body From Time Zero Extrapolated to Infinity (MRT(0-inf) Post Third Dose of MSB0010841
dayMSB0010841 30 mgMSB0010841 60 mgMSB0010841 120 mgMSB0010841 240 mg
Mean Residence Time of Drug in the Body From Time Zero Extrapolated to Infinity (MRT(0-inf) Post Third Dose of MSB001084117.57 ± 11.215.68 ± 16.319.26 ± 32.016.38 ± 11.3
PrimaryTime to Reach Maximum Observed Concentration (Tmax) Post First Dose of MSB0010841
Time frame:
0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-first dose (Day 1)
Reported as:
Median · hour
Time to Reach Maximum Observed Concentration (Tmax) Post First Dose of MSB0010841
hourMSB0010841 30 mgMSB0010841 60 mgMSB0010841 120 mgMSB0010841 240 mg
Time to Reach Maximum Observed Concentration (Tmax) Post First Dose of MSB001084172.39 (23.9 to 97.4)71.68 (24.0 to 335.8)52.00 (32.0 to 96.2)72.23 (72.0 to 168.0)
PrimaryTime to Maximum Observed Concentration (Tmax) Post Second Dose of MSB0010841
Time frame:
0 hours (pre-dose), 24, 72, 96, 168, 336 hours post-second dose (Day 15)
Reported as:
Median · hour
Time to Maximum Observed Concentration (Tmax) Post Second Dose of MSB0010841
hourMSB0010841 30 mgMSB0010841 60 mgMSB0010841 120 mgMSB0010841 240 mg
Time to Maximum Observed Concentration (Tmax) Post Second Dose of MSB001084184.2 (72.0 to 97.5)72.0 (24.1 to 96.6)83.4 (71.8 to 168.0)72.0 (24.0 to 168.0)
PrimaryTime to Reach Maximum Observed Concentration (Tmax) Post Third Dose of MSB0010841
Time frame:
0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)
Reported as:
Median · hour
Time to Reach Maximum Observed Concentration (Tmax) Post Third Dose of MSB0010841
hourMSB0010841 30 mgMSB0010841 60 mgMSB0010841 120 mgMSB0010841 240 mg
Time to Reach Maximum Observed Concentration (Tmax) Post Third Dose of MSB001084131.5 (6.0 to 95.8)31.0 (12.0 to 72.4)72.0 (31.8 to 72.5)72.0 (31.1 to 168.0)
PrimaryApparent Terminal Half-life (t1/2) Post Third Dose of MSB0010841

Terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life is calculated by dividing the natural logarithm to the base e (Log e) multiplied by (\*) 2/ λz, where 'λz' is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.

Time frame:
0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)
Reported as:
Geometric mean · day
Apparent Terminal Half-life (t1/2) Post Third Dose of MSB0010841
dayMSB0010841 30 mgMSB0010841 60 mgMSB0010841 120 mgMSB0010841 240 mg
Apparent Terminal Half-life (t1/2) Post Third Dose of MSB001084110.63 ± 17.310.50 ± 18.912.19 ± 27.910.25 ± 13.1
PrimaryTerminal Rate Constant (λz) Post Third Dose of MSB0010841

Terminal rate constant was determined from the terminal slope of the logtransformed concentration curve using linear regression on terminal data points of the curve

Time frame:
0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)
Reported as:
Geometric mean · 1/hour
Terminal Rate Constant (λz) Post Third Dose of MSB0010841
1/hourMSB0010841 30 mgMSB0010841 60 mgMSB0010841 120 mgMSB0010841 240 mg
Terminal Rate Constant (λz) Post Third Dose of MSB00108410.00 ± 17.30.00 ± 18.90.00 ± 27.90.00 ± 13.1
PrimaryApparent Clearance (CL/f) Post Third Dose of MSB0010841

Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent clearance after oral dose (CL/f) is influenced by the fraction absorbed.

Time frame:
0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)
Reported as:
Geometric mean · L/day
Apparent Clearance (CL/f) Post Third Dose of MSB0010841
L/dayMSB0010841 30 mgMSB0010841 60 mgMSB0010841 120 mgMSB0010841 240 mg
Apparent Clearance (CL/f) Post Third Dose of MSB00108410.55 ± 36.30.58 ± 33.90.59 ± 43.60.60 ± 27.1
PrimaryApparent Volume of Distribution During Terminal Phase (Vz/f) Post Third Dose of MSB0010841

Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Apparent volume of distribution during the terminal phase, calculated as Vz = Dose/AUC0-inf multiplied by elimination rate constant \[λz\]) following first dose and Dose/(AUCtau multiplied by λz) after third dose.

Time frame:
0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)
Reported as:
Geometric mean · Liters
Apparent Volume of Distribution During Terminal Phase (Vz/f) Post Third Dose of MSB0010841
LitersMSB0010841 30 mgMSB0010841 60 mgMSB0010841 120 mgMSB0010841 240 mg
Apparent Volume of Distribution During Terminal Phase (Vz/f) Post Third Dose of MSB00108418.49 ± 27.08.73 ± 38.610.39 ± 21.98.92 ± 18.8
PrimaryPercentage Peak-Trough Fluctuation (PTF) Post First Dose of MSB0010841

The peak trough fluctuation within one dosing interval, calculated as PTF (%) = (\[Cmax - Cmin\]/Cav ) multiplied by 100

Time frame:
0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-first dose (Day 1)
Reported as:
Geometric mean · percentage fluctuation
Percentage Peak-Trough Fluctuation (PTF) Post First Dose of MSB0010841
percentage fluctuationMSB0010841 30 mgMSB0010841 60 mgMSB0010841 120 mgMSB0010841 240 mg
Percentage Peak-Trough Fluctuation (PTF) Post First Dose of MSB0010841140.28 ± 3.9152.47 ± 20.4144.37 ± 13.0135.89 ± 12.3
PrimaryPercentage Peak-Trough Fluctuation (PTF) Post Third Dose of MSB0010841

The peak trough fluctuation within one dosing interval, calculated as PTF (%) = (\[Cmax - Cmin\]/Cav ) multiplied by 100

Time frame:
0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)
Reported as:
Geometric mean · percentage fluctuation
Percentage Peak-Trough Fluctuation (PTF) Post Third Dose of MSB0010841
percentage fluctuationMSB0010841 30 mgMSB0010841 60 mgMSB0010841 120 mgMSB0010841 240 mg
Percentage Peak-Trough Fluctuation (PTF) Post Third Dose of MSB001084175.26 ± 8.595.65 ± 18.971.17 ± 33.176.03 ± 28.6
PrimaryAccumulation Ratio of Cmax (Racc (Cmax))

Accumulation ratio for Cmax was calculated as Cmax, after third dose / Cmax, after first dose.

Time frame:
0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-first dose (Day 1) and 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)
Reported as:
Geometric mean · ratio
Accumulation Ratio of Cmax (Racc (Cmax))
ratioMSB0010841 30 mgMSB0010841 60 mgMSB0010841 120 mgMSB0010841 240 mg
Accumulation Ratio of Cmax (Racc (Cmax))1.56 ± 17.91.52 ± 23.51.56 ± 34.11.81 ± 9.5
PrimaryAccumulation Ratio of AUC (Racc(AUC))

Accumulation ratio for AUC, calculated as area under the serum concentration-time curve within one complete dosing interval at third dose divided by area under the serum concentration-time curve within one complete dosing interval at first dose.

Time frame:
0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-first dose (Day 1) and 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)
Reported as:
Geometric mean · ratio
Accumulation Ratio of AUC (Racc(AUC))
ratioMSB0010841 30 mgMSB0010841 60 mgMSB0010841 120 mgMSB0010841 240 mg
Accumulation Ratio of AUC (Racc(AUC))1.61 ± 15.91.50 ± 18.41.61 ± 27.41.83 ± 11.5
PrimaryMaximum Observed Concentration (Cmax) Post Second Dose of MSB0010841
Time frame:
0 hours (pre-dose), 24, 72, 96, 168, 336 hours post-second dose (Day 15)
Reported as:
Geometric mean · mcg/mL
Maximum Observed Concentration (Cmax) Post Second Dose of MSB0010841
mcg/mLMSB0010841 30 mgMSB0010841 60 mgMSB0010841 120 mgMSB0010841 240 mg
Maximum Observed Concentration (Cmax) Post Second Dose of MSB00108414.26 ± 32.79.06 ± 24.218.59 ± 23.130.98 ± 25.3
PrimaryObserved Serum Concentration Immediately Before Second Dose (Cpre) of MSB0010841

The observed serum concentration immediately before second dose.

Time frame:
Pre-dose (0 hours) on Day 15
Reported as:
Geometric mean · mcg/mL
Observed Serum Concentration Immediately Before Second Dose (Cpre) of MSB0010841
mcg/mLMSB0010841 30 mgMSB0010841 60 mgMSB0010841 120 mgMSB0010841 240 mg
Observed Serum Concentration Immediately Before Second Dose (Cpre) of MSB00108411.65 ± 30.23.74 ± 37.96.34 ± 38.311.44 ± 18.1
SecondaryPercentage of Subjects With 50% or 75% Improvement From Baseline in Psoriasis Area and Severity Index (PASI) Score

PASI: a physician assessed index that measured psoriasis severity and evaluated erythema, infiltration, and desquamation (scaling) on different body areas including the head, upper extremities, the trunk, and lower extremities. T Erythema, infiltration, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) was multiplied by the degree of involvement for each anatomic region and then multiplied by a constant. These values for each anatomic region are summed to yield the PASI score. PASI score ranged from 0 to 72, with higher scores reflecting greater disease severity. PASI 50% or 75% was defined as the percentage of participants who achieved \>=50 or 75% improvement in PASI score from Baseline.

Time frame:
Baseline up to Day 85
Reported as:
Number · percentage of subjects
Percentage of Subjects With 50% or 75% Improvement From Baseline in Psoriasis Area and Severity Index (PASI) Score
percentage of subjectsMSB0010841 30 mgMSB0010841 60 mgMSB0010841 120 mgMSB0010841 240 mgPlacebo
PASI-5010010010010050
PASI-75881001001000
SecondaryMean Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Day 43

PASI: a physician assessed index that measured psoriasis severity and evaluated erythema, infiltration, and desquamation (scaling) on different body areas including the head, upper extremities, the trunk, and lower extremities. T Erythema, infiltration, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) was multiplied by the degree of involvement for each anatomic region and then multiplied by a constant. These values for each anatomic region are summed to yield the PASI score. PASI score ranged from 0 to 72, with higher scores reflecting greater disease severity. PASI 50% or 75% was defined as the percentage of subjects who achieved \>=50 or 75% improvement in PASI score from Baseline.

Time frame:
Baseline, Day 43
Reported as:
Mean · units on a scale
Mean Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Day 43
units on a scaleMSB0010841 30 mgMSB0010841 60 mgMSB0010841 120 mgMSB0010841 240 mgPlacebo
Baseline16.91 ± 5.7519.76 ± 4.7923.35 ± 6.6018.38 ± 6.0725.49 ± 5.58
Change at Day 43-13.93 ± 4.76-17.99 ± 5.52-21.70 ± 8.52-16.68 ± 8.38-5.43 ± 7.04
SecondaryPercentage of Subjects With Static Physician's Global Assessment (sPGA) Score of Minimal or Clear and With at Least 2 Level Reduction From Baseline

The static Physician's Global Assessment (sPGA) scale rated the investigator's overall clinical assessment of a subjects plaque thickness, erythema, and scaling on a 6-point scale ranging from 0 (clear, except for residual discoloration) to 5 (majority of plaques have severe thickness, erythema, and scale). To assign a sPGA score, the investigator examined all psoriatic lesions and assigned a severity score ranging from 0 to 5 for thickness, erythema, and scaling. Scores for thickness, erythema, and scaling are summed and the mean of these 3 scores equals the overall sPGA score. Overall sPGA score ranged from 0 to 5, where lower scores indicate clinical improvement. Percentage of subjects who achieved a sPGA rating of 0 (clear) or 1 (minimal) and had at Least 2 level reduction from Baseline score were reported.

Time frame:
Day 8, 15, 22, 29, 36, 43, 50, 85
Reported as:
Number · percentage of subjects
Percentage of Subjects With Static Physician's Global Assessment (sPGA) Score of Minimal or Clear and With at Least 2 Level Reduction From Baseline
percentage of subjectsMSB0010841 30 mgMSB0010841 60 mgMSB0010841 120 mgMSB0010841 240 mgPlacebo
Day 803813110
Day 15252513560
Day 22505050670
Day 29636388780
Day 36638875670
Day 43758875670
Day 507588100890
Day 858888881000
SecondaryMean Percent Change From Baseline in the Body Surface Area (BSA) Affected by Psoriasis at Day 8, 15, 22, 29, 36, 43, 50 and 85

The BSA is the physician's evaluation for the extent of disease. The entire body area is divided into 4 districts: head, upper limbs, trunk and lower limbs to which corresponds the 10%, 20%, 30% and 40% of the entire body surface respectively. The investigator assesses the percentage of the subjects' body surface area affected by psoriasis in each district. The final affected BSA value is the sum of the percentage of each district.

Time frame:
Baseline, Day 8, 15, 22, 29, 36, 43, 50 and 85
Reported as:
Mean · percent change
Mean Percent Change From Baseline in the Body Surface Area (BSA) Affected by Psoriasis at Day 8, 15, 22, 29, 36, 43, 50 and 85
percent changeMSB0010841 30 mgMSB0010841 60 mgMSB0010841 120 mgMSB0010841 240 mgPlacebo
Change at Day 8 (n=8,8,8,8,8)0.4 ± 1.14-30.0 ± 31.23-13.7 ± 15.13-12.5 ± 23.812.9 ± 23.32
Change at Day 15 (n=8,8,8,8,8)0.4 ± 1.14-33.1 ± 35.97-20.5 ± 10.98-51.1 ± 43.17-4.2 ± 12.21
Change at Day 22 (n=8,8,8,8,8)-11.6 ± 24.90-40.2 ± 40.68-42.6 ± 27.15-68.5 ± 38.71-5.1 ± 12.69
Change at Day 29 (n=8,8,8,8,8)-22.6 ± 26.35-44.1 ± 42.53-55.9 ± 36.56-82.9 ± 34.46-0.1 ± 26.13
Change at Day 36 (8,8,7,7,7)-31.4 ± 22.96-52.7 ± 37.57-64.6 ± 37.65-83.5 ± 31.60-0.5 ± 27.92
Change at Day 43 (8,8,8,9,8)-52.6 ± 32.91-65.2 ± 28.61-75.4 ± 37.35-82.2 ± 36.64-1.5 ± 27.05
Change at Day 50 (n=8,8,8,9,8)-56.2 ± 34.71-69.4 ± 25.85-79.1 ± 32.30-82.2 ± 36.64-10.0 ± 17.87
Change at Day 85 (8,8,8,9,8)-60.4 ± 33.51-61.3 ± 33.89-82.1 ± 31.05-95.5 ± 11.02-13.0 ± 20.13
SecondaryPercentage of Subjects With Exacerbation of Psoriasis

Psoriasis exacerbation was defined as either a worsening of 25% over the baseline value of the PASI score (PASI score at any visit \>=125% of baseline PASI).

Time frame:
Baseline up to Day 85
Reported as:
Number · percentage of subjects
Percentage of Subjects With Exacerbation of Psoriasis
percentage of subjectsMSB0010841 30 mgMSB0010841 60 mgMSB0010841 120 mgMSB0010841 240 mgPlacebo
Percentage of Subjects With Exacerbation of Psoriasis000012.5

Adverse events

Collected over Baseline up to Day 85. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MSB0010841 30 mg—1/8 (12.5%)5/8 (62.5%)
MSB0010841 60 mg—0/8 (0%)5/8 (62.5%)
MSB0010841 120 mg—0/8 (0%)5/8 (62.5%)
MSB0010841 240 mg—0/9 (0%)6/9 (66.7%)
Placebo—0/8 (0%)6/8 (75%)
Most frequent serious events
Most frequent serious events
EventMSB0010841 30 mgMSB0010841 60 mgMSB0010841 120 mgMSB0010841 240 mgPlacebo
Acute vestibular syndromeEar and labyrinth disorders1/80/80/80/90/8
Most frequent other events
Showing 10 of 58
Most frequent other events
EventMSB0010841 30 mgMSB0010841 60 mgMSB0010841 120 mgMSB0010841 240 mgPlacebo
BronchitisInfections and infestations0/82/80/80/90/8
HeadacheNervous system disorders0/82/80/81/90/8
PruritusSkin and subcutaneous tissue disorders2/81/80/81/91/8
PsoriasisSkin and subcutaneous tissue disorders0/80/80/80/92/8
LeukopeniaBlood and lymphatic system disorders0/81/80/80/90/8
Lacrimation increasedEye disorders0/81/80/80/90/8
Hypoaesthesia oralGastrointestinal disorders1/80/80/80/90/8
ToothacheGastrointestinal disorders1/80/80/80/90/8
AstheniaGeneral disorders0/80/81/80/90/8
Influenza like illnessGeneral disorders0/80/81/80/90/8

Baseline characteristics

Safety analysis set included all 41 subjects who received at least 1 dose of investigational medicinal product (IMP) (MSB0010841 or placebo).

Age, Continuous
Age, Continuous(years)MSB0010841 30 mgMSB0010841 60 mgMSB0010841 120 mgMSB0010841 240 mgPlaceboTotal
Mean48.6 ± 13.2442.1 ± 19.5743.8 ± 13.5944.8 ± 15.6546.1 ± 14.5745.1 ± 14.87
Gender
Gender(Participants)MSB0010841 30 mgMSB0010841 60 mgMSB0010841 120 mgMSB0010841 240 mgPlaceboTotal
Female102126
Male7868635
08

Study locations

1 site
  • Please contact the Merck KGaA Communication Center
    Darmstadt, Germany
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2014, a primary completion of Aug 2015 and a completion of Aug 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2017, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2014
First posted
Jun 5, 2014
Start
Aug 2014
Primary completionActual
Aug 2015
CompletionActual
Aug 2015
Results first posted
Jan 19, 2017
Last update
Jan 19, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 19, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02156466
Responsible party
Sponsor
First posted
Jun 5, 2014
Start date
Aug 2014
Primary completion
Aug 2015
Completion
Aug 2015
Results posted
Jan 19, 2017
Last update
Jan 19, 2017

Study contacts

Medical Responsible
study director · Merck KGaA, Darmstadt, Germany
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sonelokimab

Start the discussion